Ionis (IONS) Q2 2026 Earnings Call Transcript

Ionis reported Q2 2026 total revenue of $268M (+56% YoY excluding the prior-year one-time Sapablursen payment) and Q2 commercial revenue of $119M (+15%), driven primarily by DAWNZERA ($26M, +63% QoQ) while TRYNGOLZA product sales were $5M impacted by the April 1 WAC price reduction. Full-year 2026 guidance was maintained at $875M–$900M revenue and non-GAAP operating loss of $425M–$475M, with TRYNGOLZA expected to return to growth in H2 ($100M–$110M) and DAWNZERA ($110M–$120M). Cash stood at $2.1B after repayment of 0% convertible notes in April, but management flagged disappointment from the CARDIO-TTRansform Phase III miss for Eplontersen while keeping the long-term cash-flow breakeven target for 2028.

Analysis

IONS is trading more like a commercial launch platform than a pure R&D story now. The key second-order winner is the company itself: owned-product mix should improve gross margin quality over the next 2-4 quarters, while partner royalties provide downside support, so the real valuation debate shifts from "can they sell?" to "how fast can access normalize?" The immediate loser is the ATTR-cardiomyopathy optionality embedded in the TTR franchise; that overhang is more meaningful for AZN than for IONS because it pressures a larger strategic story, but it does not impair the near-term cash engine.

The next 30-90 days are about reimbursement mechanics, not biology. sHTG uptake can look strong in prescription intent yet still miss revenue expectations if prior auths stay manual and payer policies lag; the lack of a clean ICD-10 path is a real friction point that can cap the first-wave conversion rate. By contrast, the 6-18 month setup is better: if Zilganersen and Bepirovirsen clear regulatory gates, IONS can de-risk cash flow breakeven without needing a perfect outcome from Pelacarsen.

Contrarian view: consensus may be overreacting to the TTR miss and underappreciating that the stock can re-rate on execution evidence from launches, but it may simultaneously be overestimating how quickly the sHTG market becomes frictionless. The falsifier is simple: if prescription growth stalls while payer coverage remains exception-based into Q4, the bull case for a steep commercial ramp and 2028 breakeven slides materially.

Key Decisions for Investors

• Accumulate IONS on post-call weakness over the next 1-2 weeks; use the TTR disappointment as an entry point if the stock trades at a discount to its cash-plus-launch pipeline value.
• Pair trade: long IONS / short ALNY for the next 1-3 months to express relative resilience of the owned-launch platform versus TTR-related sentiment risk; cut the pair if IONS access data disappoints or ALNY reasserts ATTR leadership.
• Buy a small IONS call spread into the Sept.-Oct. catalyst window only after monitoring initial payer coverage and script conversion; the upside is a multiple reset if Zilganersen/Bepirovirsen de-risk, but premium should be limited until launch friction is visible.
• Set a watch item on weekly TRYNGOLZA prescription growth and payer-policy expansion; if conversion remains exception-driven beyond Q4, trim longs because the market may be overpricing a 2027 ramp.